143840-91-9

Basic information

• Product Name: 1-[4-(2-Chloro-2-pyridin-3-yl-ethyl)-piperazin-1-yl]-2,2-diphenyl-ethanone
• CAS NO: 143840-91-9
• Molecular Weight: 419.954
• Mol File: 143840-91-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[4-(2-Chloro-2-pyridin-3-yl-ethyl)-piperazin-1-yl]-2,2-diphenyl-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(2-Chloro-2-pyridin-3-yl-ethyl)-piperazin-1-yl]-2,2-diphenyl-ethanone(143840-91-9)
• EPA Substance Registry System: 1-[4-(2-Chloro-2-pyridin-3-yl-ethyl)-piperazin-1-yl]-2,2-diphenyl-ethanone(143840-91-9)

Safety Data

• Hazardous Substances Data: 143840-91-9(Hazardous Substances Data)

Upstream product

• 137075-31-1 1-(diphenylacetyl)-4-<2-(3-pyridyl)-2-oxoethyl>piperidine 
• 117-34-0 2,2-diphenylacetic acid 
• 137075-32-2 1-(diphenylacetyl)-4-<2-(3-pyridyl)-2-hydroxoethyl>piperazine 
• 67199-20-6 1-Diphenylacetyl-4-formylpiperazine 
• 67199-13-7 N-(2,2-diphenylacetyl)piperazine 

Downstream Products

• 137074-71-6 1-(diphenylacetyl)-4-(2-(pyridin-3-yl)-2-cyanoethyl)-piperazine 

Relevant articles and documents

(Pyridylcyanomethyl)piperazines as orally active PAF antagonists

A series of (pyridylcyanomethyl)piperazines was prepared and evaluated for PAF-antagonist activity. Compounds were tested in vitro in a PAF-induced platelet aggregation assay and in vivo in a PAF-induced hypotension test in normotensive rats. Oral activity was ascertained through a PAF-induced mortality test in mice. The main structure-activity trends of the series were established. Activity was mainly found in four skeletons: 1-acyl-4-(3- pyridylcyanomethyl)-piperazine, 1-acyl-4-(4-pyridylcyanomethyl)piperazine, 1- acyl-4-(3-pyridylcyanomethyl)piperidine, and 1-acyl-4-cyano-4-(3- pyridylamino)piperidine. The acyl substituents, diphenylacetyl and 3,3- diphenylpropionyl, provided the most active compounds, and the introduction of an amine or hydroxy group in the 3,3-diphenylpropionyl substituent led to further improvement in oral activity. As a result, three of the most active compounds (100, 114, and 115) have been selected for further pharmacological development.